SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : IMNR - Immune Response -- Ignore unavailable to you. Want to Upgrade?

To: Chris Wilkinson who wrote (139)10/21/1997 9:36:00 PM
From: Robert DeHaven  Respond to of 1510
 
The FDA can speed up the apporoval process for Remune if the data is promising. I have heard "talk" that this is the case. If so, IMNR should be partnering with a mfr. that would be able to bring production quantitiy of Remune to market. This fact was outlined in their last 10 k I believe.

Also, I agree there is more good stuff in the pipeline....

Good luck.

Bob



To: Chris Wilkinson who wrote (139)10/23/1997 5:24:00 PM
From: Charles Hill  Read Replies (1) | Respond to of 1510
 
I too am betting that Remune will come through for IMNR. As for the arthritis therapy, think you need to bear in mind that Immunex (IMNX) is way ahead on getting a product to market --- and they appear to have a very good product.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News